<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364559</url>
  </required_header>
  <id_info>
    <org_study_id>29-09 ROICH</org_study_id>
    <nct_id>NCT00364559</nct_id>
  </id_info>
  <brief_title>Effect of Rosuvastatin in Intracerebral Hemorrhage</brief_title>
  <official_title>Effect of Rosuvastatin on Outcome by NIHSS After Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de San Luis Potosí</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Autonoma de San Luis Potosí</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rosuvastatin is effective in the management
      of acute phase of intracerebral hemorrhage and if it impact outcome by NIHSS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The intracerebral hemorrhage (ICH) is a frequent problem of health, with high
      morbid-mortality. In addition it originates expensive expenses in health care systems.

      ICH produces damage by mass effect, then by biochemical ways which are activated and they
      carry to secondary damage. Many studies have been conducted for explaining secondary injury,
      now we know there are ischemic changes related maybe with changes in cerebral flow and
      metabolism, in addition to activate inflammatory ways. Many drugs and measures has been
      ineffective for getting best outcome, without success.

      Statins or inhibitors of HMG CoA reductase are drugs used in dyslipidemia, frequently for
      reduction in LDL. Experimental and clinical studies in stroke and ICH have shown improvement
      in outcome. The toxicity related to statin is myopathy and hepatopathy, both with low
      incidence without fatal cases. Rosuvastatin has been postulated be the most powerful with
      longest life and toxicity similar to another statins.

      We have designed this study to demonstrate if the administration of rosuvastatin in the first
      24 hours and by 14 days has improvement in outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NIHSSº</measure>
    <time_frame>basal and discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survivor</measure>
    <time_frame>within 1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A, Active B, Historical Register</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20 mg 10 days daily</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or Women &gt;16 and &lt; 80 years with ICH and hospital attention in less 24 hours

          -  Confirmation by CT scan

          -  Acceptance by family

        Exclusion Criteria:

          -  History of stroke

          -  History of neurological disease, head injury o psychiatric disorder with disability

          -  Glasgow less than 9

          -  Administration 24 hours before: fibrates, niacin, ciclosporin, azoles, macrolides,
             inhibitors of protease, nefazodone, verapamil, diltiazem, amiodarone.

          -  Use before hospital of: mannitol, barbiturates, corticosteroids, calcium antagonists

          -  Any lesion which needs surgery

          -  Allergy to drug used

          -  cerebral death

          -  Hepatic disease (Child B y C) or myopathy (or) history

          -  Management in other Hospital

          -  Pregnancy

          -  ICH major than 60 ml.

          -  hypothyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ildefonso Rodríguez-Leyva, Neurology</last_name>
    <role>Study Director</role>
    <affiliation>Neurología, Hospital Central &quot;Dr. ignacio Morones Prieto&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Humberto Tapia-Perez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facultad de Medicina UASLP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo J, Rodriguez-Leyva I, Herrera-Gonzalez LB. [Statins and brain protection mechanisms]. Rev Neurol. 2007 Sep 16-30;45(6):359-64. Review. Spanish.</citation>
    <PMID>17899518</PMID>
  </reference>
  <reference>
    <citation>Tapia-Pérez H, Torres-Corzo J, Sanchez-Aguilar M, González-Aguirre D, Rodríguez-Leyva I, Teniente-Sánchez AE, Gordillo-Moscoso A. [A clinical-epidemiological approximation to intracerebral hemorrhage in a Mexican hospital: analysis of factors associated to mortality]. Rev Neurol. 2008 Jan 16-31;46(2):67-72. Spanish.</citation>
    <PMID>18247276</PMID>
  </reference>
  <results_reference>
    <citation>Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, Rodriguez-Leyva I, Gonzalez-Aguirre D, Gordillo-Moscoso A, Chalita-Williams C. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Cent Eur Neurosurg. 2009 Feb;70(1):15-20. doi: 10.1055/s-0028-1082064. Epub 2009 Feb 5.</citation>
    <PMID>19197830</PMID>
  </results_reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2006</study_first_submitted>
  <study_first_submitted_qc>August 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2006</study_first_posted>
  <last_update_submitted>March 25, 2009</last_update_submitted>
  <last_update_submitted_qc>March 25, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2009</last_update_posted>
  <responsible_party>
    <organization>Humberto Tapia</organization>
  </responsible_party>
  <keyword>intracerebral hemorrhage</keyword>
  <keyword>statins</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

